GTL001, a Bivalent Therapeutic Vaccine Against Human Papillomavirus 16 and 18, Induces Antigen-Specific CD8+ T Cell Responses Leading to Tumor Regression

PLoS ONE - United States
doi 10.1371/journal.pone.0174038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Human HSP70 and Modified HPV16 E7 Fusion DNA Vaccine Induces Enhanced Specific CD8+ T Cell Responses and Anti-Tumor Effects

Oncology Reports
MedicineCancer ResearchOncology
2009English

Intravaginal TLR Agonists Increase Local Vaccine-Specific CD8 T Cells and Human Papillomavirus-Associated Genital-Tumor Regression in Mice

Mucosal Immunology
AllergyImmunology
2012English

GTL001, a Therapeutic Vaccine for Women Infected With Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial

Clinical Cancer Research
Cancer ResearchOncology
2016English

Persistent Antigen at Vaccination Sites Induces Tumor-Specific CD8+ T Cell Sequestration, Dysfunction and Deletion

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2013English

Risk of Miscarriage With Bivalent Vaccine Against Human Papillomavirus (HPV) Types 16 and 18: Pooled Analysis of Two Randomised Controlled Trials

BMJ
2010English

MHC-based Detection of Antigen-Specific CD8+ T Cell Responses

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2010English

Rift Valley Fever Virus Vaccination Induces Long-Lived, Antigen-Specific Human T Cell Responses

npj Vaccines
Infectious DiseasesImmunologyPharmacology
2020English

Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+T Cell Response

Journal of Immunology
AllergyImmunology
2018English

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine

Drugs
Pharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy